Oral Antiviral Market Expected to Reach $43,394.00 Million by 2031—Allied Market Research

According to a new report published by Allied Market Research, titled, “Oral Antiviral Market," The oral antiviral market size was valued at $35,213.48 million in 2021 and is estimated to reach $43,394.00 million by 2031, exhibiting a CAGR of 2.1% from 2022 to 2031.  

The choice of oral antiviral agent depends on several factors such as type of virus causing the infection, the stage of the infection, the severity of symptoms, and the patient's age, medical history, and other medications. 

The major factors driving the growth of the oral antiviral market are increase in prevalence of antiviral infections, rise in number of product approvals for treating viral infections and increase in awareness about viral infection & treatment options available. For instance, according to report World Health Organization 2022, 350 million people in the world are living with viral hepatitis. Thus, a rise in the prevalence of hepatitis cases is anticipated to drive the growth of the market.  

Further, a rise in regulatory approvals for treating viral infections is expected to drive the growth of the market during the forecast period. For instance, in August 2022, Genentech (member of the Roche Group), received U.S. Food and Drug Administration (FDA) approval for Xofluza (baloxavir marboxil) for the treatment of influenza in children aged five and older. Thus, a rise in the number of product approvals for treating viral infections such as influenza, is expected to drive the growth of the market. 

Furthermore, rise in adoption of strategies such as agreement and partnership by key players of market to cater the demand of oral antiviral drugs are the upcoming oral antiviral market trends. For instance, in July 2022, ViiV Healthcare, and the Medicines Patent Pool (MPP) announced the signing of a new voluntary licensing agreement to develop, manufacture and supply generic versions of cabotegravir LA, the first long-acting HIV prevention medicine, in 90 countries. Thus, a rise in the adoption of such key strategies is anticipated to contribute to the growth of the market. Moreover, increased awareness about early diagnosis & treatment of viral infections, and increased access to healthcare services, have contributed to the growth of the oral antiviral drug market. This has resulted in more people being diagnosed and treated for viral infections, which has increased the demand for oral antiviral drugs. 

However, stringent regulations regarding approval of oral antiviral drugs and side effects associated with it are the factors restraining the growth of oral antiviral market. In addition, as patents of some oral antiviral drugs expire, generic versions become available, which can reduce the market share of the original drug. 

On the basis of indication, the market is categorized into hepatitis, human immunodeficiency virus (HIV), influenza, and others. The human immunodeficiency virus (HIV) segment accounted for the oral antiviral market share in 2021 and is expected to remain dominant during forecast period, owing to rise in prevalence of HIV cases across the globe and rise in number of key players offering novel medications. The hepatitis segment is expected to witness highest CAGR during the forecast period owing to rise in prevalence of hepatitis cases and rise in number of product approvals for treating hepatitis infection. 

 On the basis of drug class, the market is categorized into protease inhibitors, reverse transcriptase inhibitors, and others. The reverse transcriptase inhibitors segment accounted for largest share in 2021 and is expected to remain dominant during forecast period, owing to increase in use of these drugs for treating HIV and hepatitis as these drugs are highly effective and used in combination with other oral antivirals for treating viral infections. The others segment is expected to witness highest CAGR during the forecast period owing to rise in availability of such class of drugs for treating the viral infections. 

On the basis of distribution channel, the market is categorized into hospital pharmacies, drug stores and retail pharmacies and online providers. The drug stores and retail pharmacies segment occupied largest share in 2021 and is expected to remain dominant during forecast period owing to increase in preference of the people toward retail pharmacies, as retail pharmacies guide regarding medications and usage during treatment period.  The online providers segment is projected to register the highest CAGR during the forecast period owing to the rise in popularity of online pharmacies and the number of users preferring online pharmacies.  

Region wise, the North America accounted for largest share in 2021 and is expected to remain dominant during the forecast period owing to rise in prevalence of viral infections such as hepatitis C, presence of key players offering oral antivirals and rise in healthcare infrastructure drive the growth of oral antiviral market. However, Asia-Pacific is anticipated to witness notable growth, owing to increase in investments for development of oral antiviral agents, increase in viral infection cases and number of pipeline medications for treating viral infections, thereby driving the oral antiviral market growth during the forecast period.  

Key findings of the study 

• On the basis of indication, the HIV segment dominated the market in terms of revenue in 2021. 
• On the basis of drug class, reverse transcriptase inhibitors segment dominated the oral antiviral industry in terms of revenue in 2021. 
• On the basis of distribution channel, the drug stores and retail pharmacies segment dominated the market in terms of revenue in 2021. However, the online providers segment is anticipated to grow at the highest CAGR during the forecast period. 
• Region wise, North America generated the largest revenue in 2021. However, Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.